Aemcolo/Relafalk, Cosmo’s novel antibiotic for colon infections, was approved in its first indication for treating travelers’ diarrhea in November, with US and EU launches in Q1 2019. Cosmo’s Aries will commercialize Aemcolo in the US, while Dr. Falk will market the antibiotic under the Relafalk brand in the EU/ROW together with future distribution partners. Aemcolo/Relafalk is likely Cosmo’s most underestimated pipeline product with EUR 550+ peak sales in all indications. The company has ample cash to finance all its development and commercialization plans and strengthen its gastrointestinal/endoscopy product offering through external transactions, thanks to the placement of EUR 175 mn convertible bonds end November.
Key catalysts include:
• MethyleneBlue EU filing colonoscopy (early 2019)
• Aemcolo/Relafalk phase II results IBS-D (early 2019)
• Remimazolam US filing procedural sedation (Q1 2019)
Find the full report as PDF below.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1